Q002: A BEST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS

In parallel to Q001 we are developing Q002, a new best-in-class topical formulation of the proven topical drug, tacrolimus.  Q002 aims to improve the overall patient experience over current treatments whilst effectively treating the disease.